Gilead Sciences Inc. GILD, +1.08% announced Monday afternoon that it plans to ask the Food and Drug Administration to approve an arthritis drug this year. Gilead, in partnership with Galapagos NV GLPG, +3.53% has been testing a drug known as filgotinib for rheumatoid arthritis, and the latest study results excited investors in March. In a news release Monday, Gilead said that it met with the FDA to discuss those test results recently. “As a result of this discussion, a path forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 2019,” the release said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.